meta:
  schema_version: '1.0'
  compatible_engine: cellswarm>=2.0
drug_id: tiragolumab
generic_name: Tiragolumab
brand_name: N/A
drug_class: immune_checkpoint_inhibitor
subclass: anti_TIGIT
molecular_type: monoclonal_antibody
fda_status: investigational
approved_indications: []
targets:
- name: TIGIT
  gene: TIGIT
  type: receptor
  action: antagonist
  selectivity: high
cell_effects:
  CD8_T:
    direct: true
    state_effects:
    - parameter: exhaustion
      direction: decrease
      rate_per_step: 0.05
    - parameter: activation
      direction: increase
      rate_per_step: 0.04
    functional_effects:
    - action: attack
      probability_modifier: 0.12
  Tumor:
    direct: false
    state_effects:
    - parameter: immune_evasion
      direction: decrease
      rate_per_step: 0.02
  Treg:
    direct: true
    state_effects:
    - parameter: suppressive_activity
      direction: decrease
      rate_per_step: 0.03
    notes: TIGIT expressed on Tregs
  Macrophage:
    direct: false
    state_effects: []
  NK:
    direct: true
    state_effects:
    - parameter: activation
      direction: increase
      rate_per_step: 0.06
    - parameter: cytotoxicity
      direction: increase
      rate_per_step: 0.05
    notes: TIGIT is a key NK cell inhibitory receptor
  B_cell:
    direct: false
    state_effects: []
environment_effects:
- field: IFN_gamma
  action: amplify
  magnitude: 0.08
pharmacokinetics:
  administration: IV
  standard_dose: 600 mg q3w
  onset_steps: 1
  peak_steps: 3
  half_life_steps: 14
  concentration_curve: plateau
  steady_state_fraction: 0.8
dose_response:
  model: hill
  ec50: 0.6
  hill_coefficient: 1.8
  max_effect: 0.85
cancer_specific_modifiers:
  TNBC:
    efficacy_modifier: 0.4
    notes: Investigational
  Melanoma:
    efficacy_modifier: 0.5
    notes: Investigational
  NSCLC:
    efficacy_modifier: 0.6
    notes: CITYSCAPE trial with atezo
  CRC-MSI-H:
    efficacy_modifier: 0.4
    notes: Investigational
  CRC-MSS:
    efficacy_modifier: 0.15
    notes: Unlikely effective alone
  Ovarian:
    efficacy_modifier: 0.3
    notes: Investigational
resistance:
- mechanism: Compensatory PD-1/LAG-3 upregulation
  onset_steps: 15
  probability: 0.15
references:
- description: 'CITYSCAPE: Tiragolumab+Atezo in NSCLC. Cho et al. Lancet Oncol 2022'
  pmid: '35576957'
  verified: true
